News & Updates

The high clinical response levels achieved with bimekizumab over 48 weeks persist up to week 96 in patients with moderate-to-severe plaque psoriasis, results of the BE RADIANT phase IIIb trial have shown. In addition, those on secukinumab who switched to bimekizumab have achieved similar responses at 96 weeks.

A cross-sectional analysis has found an association between insomnia, poor sleep quality, and extremes of sleep duration and increased COVID-19 infection and hospitalization.

Early adolescents with higher vitamin D levels at baseline appear to be at lower risk of depression, a study has found.

In the treatment of patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, and locally advanced nonsmall cell lung cancer (NSCLC), the use of durvalumab immunotherapy in combination with curative radiotherapy yields survival gains with tolerable adverse events (AEs), as shown in the results of the phase II DOLPHIN trial.

Exposure to high levels of fine particulate matter (PM2.5) appears to contribute to an increased risk of oestrogen receptor (ER)-positive breast cancer, as shown in a study.

A recent study provides further evidence to support the current recommendations for empirical intravenous treatment with gentamicin and ampicillin for febrile infants younger than 2 months with suspected urinary tract infection (UTI).